{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:47:18Z","timestamp":1791920838856,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Zhejiang Medical and Health Science and Technology Plan project","award":["2015KYB432"],"award-info":[{"award-number":["2015KYB432"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s12282-020-01048-5","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T11:03:09Z","timestamp":1579518189000},"page":"573-585","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["lncRNA TCL6 correlates with immune cell infiltration and indicates worse survival in breast cancer"],"prefix":"10.1007","volume":"27","author":[{"given":"Yaqiong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4429-1033","authenticated-orcid":false,"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,20]]},"reference":[{"key":"1048_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1048_CR2","first-page":"548","volume":"68","author":"N Biglia","year":"2016","unstructured":"Biglia N, D'Alonzo M, Sgro LG, Tomasi Cont N, Bounous V, Robba E. Breast cancer treatment in mutation carriers: surgical treatment. Minerva Ginecol. 2016;68:548\u201356.","journal-title":"Minerva Ginecol."},{"key":"1048_CR3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.6004\/jnccn.2015.0060","volume":"13","author":"WJ Gradishar","year":"2015","unstructured":"Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. Breast cancer version 2.2015. J Natl Compr Cancer Netw. 2015;13:448\u201375.","journal-title":"J Natl Compr Cancer Netw."},{"key":"1048_CR4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10549-010-0746-x","volume":"120","author":"EA Rakha","year":"2010","unstructured":"Rakha EA, Reis-Filho JS, Ellis IO. Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat. 2010;120:293\u2013308.","journal-title":"Breast Cancer Res Treat."},{"key":"1048_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1365-2559.2007.02897.x","volume":"52","author":"SJ Payne","year":"2008","unstructured":"Payne SJ, Bowen RL, Jones JL, Wells CA. Predictive markers in breast cancer\u2014the present. Histopathology. 2008;52:82\u201390.","journal-title":"Histopathology"},{"key":"1048_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.tcb.2017.11.008","volume":"28","author":"C Lin","year":"2018","unstructured":"Lin C, Yang L. Long noncoding RNA in cancer: wiring signaling circuitry. Trends Cell Biol. 2018;28:287\u2013301.","journal-title":"Trends Cell Biol."},{"key":"1048_CR7","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1158\/0008-5472.CAN-16-2634","volume":"77","author":"A Bhan","year":"2017","unstructured":"Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77:3965\u201381.","journal-title":"Cancer Res."},{"key":"1048_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrd.2016.117","volume":"16","author":"M Matsui","year":"2017","unstructured":"Matsui M, Corey DR. Non-coding RNAs as drug targets. Nat Rev Drug Discov. 2017;16:167\u201379.","journal-title":"Nat Rev Drug Discov."},{"key":"1048_CR9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.cca.2015.02.046","volume":"444","author":"M Isin","year":"2015","unstructured":"Isin M, Dalay N. LncRNAs and neoplasia. Clin Chim Acta. 2015;444:280\u20138.","journal-title":"Clin Chim Acta."},{"key":"1048_CR10","doi-asserted-by":"publisher","first-page":"e12381","DOI":"10.1111\/cpr.12381","volume":"50","author":"J Li","year":"2017","unstructured":"Li J, Li Z, Zheng W, Li X, Wang Z, Cui Y, et al. LncRNA-ATB: an indispensable cancer-related long noncoding RNA. Cell Prolif. 2017;50:e12381.","journal-title":"Cell Prolif."},{"key":"1048_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/978-981-10-5203-3_7","volume":"1008","author":"A Renganathan","year":"2017","unstructured":"Renganathan A, Felley-Bosco E. Long noncoding rnas in cancer and therapeutic potential. Adv Exp Med Biol. 2017;1008:199\u2013222.","journal-title":"Adv Exp Med Biol."},{"key":"1048_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.intimp.2018.09.031","volume":"65","author":"X Li","year":"2018","unstructured":"Li X, Li N. LncRNAs on guard. Int Immunopharmacol. 2018;65:60\u20133.","journal-title":"Int Immunopharmacol."},{"key":"1048_CR13","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1002\/jcp.26568","volume":"233","author":"WD Yu","year":"2018","unstructured":"Yu WD, Wang H, He QF, Xu Y, Wang XC. Long noncoding RNAs in cancer-immunity cycle. J Cell Physiol. 2018;233:6518\u201323.","journal-title":"J Cell Physiol."},{"key":"1048_CR14","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s13277-015-4572-y","volume":"37","author":"S Malih","year":"2016","unstructured":"Malih S, Saidijam M, Malih N. A brief review on long noncoding RNAs: a new paradigm in breast cancer pathogenesis, diagnosis and therapy. Tumour Biol. 2016;37:1479\u201385.","journal-title":"Tumour Biol."},{"key":"1048_CR15","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.18632\/oncotarget.11011","volume":"8","author":"H Su","year":"2017","unstructured":"Su H, Sun T, Wang H, Shi G, Zhang H, Sun F, et al. Decreased TCL6 expression is associated with poor prognosis in patients with clear cell renal cell carcinoma. Oncotarget. 2017;8:5789\u201399.","journal-title":"Oncotarget."},{"key":"1048_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.21037\/cco.2016.11.01","volume":"6","author":"F Bertucci","year":"2017","unstructured":"Bertucci F, Chaffanet M, Birnbaum D. An ICGC major achievement in breast cancer: a comprehensive catalog of mutations and mutational signatures. Chin Clin Oncol. 2017;6:4.","journal-title":"Chin Clin Oncol."},{"key":"1048_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415\u201321.","journal-title":"Nature"},{"key":"1048_CR18","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA."},{"key":"1048_CR19","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108\u201310.","journal-title":"Cancer Res."},{"key":"1048_CR20","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10549-009-0674-9","volume":"123","author":"B Gyorffy","year":"2010","unstructured":"Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123:725\u201331.","journal-title":"Breast Cancer Res Treat."},{"key":"1048_CR21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2741\/s427","volume":"7","author":"Y Liu","year":"2015","unstructured":"Liu Y, Sharma S, Watabe K. Roles of lncRNA in breast cancer. Front Biosci (Sch Ed). 2015;7:94\u2013108.","journal-title":"Front Biosci (Sch Ed)."},{"key":"1048_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12935-018-0674-0","volume":"18","author":"X Bin","year":"2018","unstructured":"Bin X, Hongjian Y, Xiping Z, Bo C, Shifeng Y, Binbin T. Research progresses in roles of LncRNA and its relationships with breast cancer. Cancer Cell Int. 2018;18:179.","journal-title":"Cancer Cell Int."},{"key":"1048_CR23","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1038\/sj.onc.1203604","volume":"19","author":"M Saitou","year":"2000","unstructured":"Saitou M, Sugimoto J, Hatakeyama T, Russo G, Isobe M. Identification of the TCL6 genes within the breakpoint cluster region on chromosome 14q32 in T-cell leukemia. Oncogene. 2000;19:2796\u2013802.","journal-title":"Oncogene"},{"key":"1048_CR24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.4196\/kjpp.2019.23.6.449","volume":"23","author":"S Tao","year":"2019","unstructured":"Tao S, Wang W, Liu P, Wang H, Chen W. Long non-coding RNA T-cell leukemia\/lymphoma 6 serves as a sponge for miR-21 modulating the cell proliferation of retinoblastoma through PTEN. Korean J Physiol Pharmacol. 2019;23:449\u201358.","journal-title":"Korean J Physiol Pharmacol."},{"key":"1048_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/bcr2889","volume":"13","author":"DL Holliday","year":"2011","unstructured":"Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011;13:215.","journal-title":"Breast Cancer Res."},{"key":"1048_CR26","doi-asserted-by":"publisher","first-page":"547","DOI":"10.4161\/cam.23332","volume":"6","author":"M Perrot-Applanat","year":"2012","unstructured":"Perrot-Applanat M, Di Benedetto M. Autocrine functions of VEGF in breast tumor cells: adhesion, survival, migration and invasion. Cell Adhes Migr. 2012;6:547\u201353.","journal-title":"Cell Adhes Migr"},{"issue":"Suppl 1","key":"1048_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1634\/theoncologist.5-suppl_1-37","volume":"5","author":"G Gasparini","year":"2000","unstructured":"Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist. 2000;5(Suppl 1):37\u201344.","journal-title":"Oncologist"},{"key":"1048_CR28","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234\u201348.","journal-title":"Nat Rev Clin Oncol"},{"key":"1048_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2017.05.033","volume":"451","author":"B Groner","year":"2017","unstructured":"Groner B, von Manstein V. Jak Stat signaling and cancer: opportunities, benefits and side effects of targeted inhibition. Mol Cell Endocrinol. 2017;451:1\u201314.","journal-title":"Mol Cell Endocrinol"},{"key":"1048_CR30","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.2174\/1871520615666150518092547","volume":"15","author":"C Zhang","year":"2015","unstructured":"Zhang C, Ben A, Reville J, Calabrese V, Villa NN, Bandyopadhyay M, et al. Immunotherapeutic impact of toll-like receptor agonists in breast cancer. Anticancer Agents Med Chem. 2015;15:1134\u201340.","journal-title":"Anticancer Agents Med Chem"},{"key":"1048_CR31","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1126\/science.1251456","volume":"344","author":"P Wang","year":"2014","unstructured":"Wang P, Xue Y, Han Y, Lin L, Wu C, Xu S, et al. The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation. Science. 2014;344:310\u20133.","journal-title":"Science"},{"key":"1048_CR32","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/jcp.24918","volume":"230","author":"JY Kan","year":"2015","unstructured":"Kan JY, Wu DC, Yu FJ, Wu CY, Ho YW, Chiu YJ, et al. Chemokine (C\u2013C motif) ligand 5 is involved in tumor-associated dendritic cell-mediated colon cancer progression through non-coding RNA MALAT-1. J Cell Physiol. 2015;230:1883\u2013944.","journal-title":"J Cell Physiol."},{"key":"1048_CR33","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.3892\/or.2017.5399","volume":"37","author":"T Doi","year":"2017","unstructured":"Doi T, Ishikawa T, Okayama T, Oka K, Mizushima K, Yasuda T, et al. The JAK\/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. Oncol Rep. 2017;37:1545\u201354.","journal-title":"Oncol Rep."},{"key":"1048_CR34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3390\/vaccines7040149","volume":"7","author":"R Saleh","year":"2019","unstructured":"Saleh R, Toor SM, Khalaf S, Elkord E. Breast cancer cells and PD-1\/PD-L1 blockade upregulate the expression of PD-1, CTLA-4, TIM-3 and LAG-3 immune checkpoints in CD4(+) T cells. Vaccines (Basel). 2019;7:149.","journal-title":"Vaccines (Basel)."},{"key":"1048_CR35","doi-asserted-by":"publisher","first-page":"96793","DOI":"10.1172\/jci.insight.96793","volume":"3","author":"D Goltz","year":"2018","unstructured":"Goltz D, Gevensleben H, Vogt TJ, Dietrich J, Golletz C, Bootz F, et al. CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients. JCI Insight. 2018;3:96793.","journal-title":"JCI Insight."}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-020-01048-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12282-020-01048-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-020-01048-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:26:57Z","timestamp":1611016017000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12282-020-01048-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,20]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1048"],"URL":"https:\/\/doi.org\/10.1007\/s12282-020-01048-5","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,20]]},"assertion":[{"value":"16 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of The Cancer Genome Atlas Human Subjects Protection and Data Access Policies, adopted by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}